- Home
- LOGC vs CHRS Comparison
LOGC vs CHRS Comparison
Compare LOGC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- CHRS
- Stock Information
- Founded
- LOGC 2010
- CHRS 2010
- Country
- LOGC United States
- CHRS United States
- Employees
- LOGC N/A
- CHRS 235
- Industry
- LOGC Catalog/Specialty Distribution
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOGC Consumer Discretionary
- CHRS Health Care
- Exchange
- LOGC Nasdaq
- CHRS Nasdaq
- Market Cap
- LOGC 175.8M
- CHRS 134.4M
- IPO Year
- LOGC 2020
- CHRS 2014
- Fundamental
- Price
- LOGC $7.73
- CHRS $1.22
- Analyst Decision
- LOGC
- CHRS Strong Buy
- Analyst Count
- LOGC 0
- CHRS 4
- Target Price
- LOGC N/A
- CHRS $5.38
- AVG Volume (30 Days)
- LOGC 172.4K
- CHRS 2.4M
- Earning Date
- LOGC 03-03-2025
- CHRS 03-12-2025
- Dividend Yield
- LOGC N/A
- CHRS N/A
- EPS Growth
- LOGC N/A
- CHRS N/A
- EPS
- LOGC N/A
- CHRS N/A
- Revenue
- LOGC $96,000,000.00
- CHRS $304,340,000.00
- Revenue This Year
- LOGC N/A
- CHRS $2.47
- Revenue Next Year
- LOGC $422.91
- CHRS N/A
- P/E Ratio
- LOGC N/A
- CHRS N/A
- Revenue Growth
- LOGC N/A
- CHRS 44.19
- 52 Week Low
- LOGC $4.20
- CHRS $0.66
- 52 Week High
- LOGC $8.24
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- LOGC 68.64
- CHRS 44.03
- Support Level
- LOGC $7.36
- CHRS $1.03
- Resistance Level
- LOGC $6.97
- CHRS $1.23
- Average True Range (ATR)
- LOGC 0.29
- CHRS 0.13
- MACD
- LOGC 0.11
- CHRS -0.02
- Stochastic Oscillator
- LOGC 100.00
- CHRS 38.89
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.